Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label cefiderocol PK and safety study in hospitalized neonates and young infants with suspected or confirmed aerobic gram-negative bacterial infection
MOH_2024-01-23_013206Phase 2Not yet recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cefiderocol in Gram-negative bacterial infection (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Pharmacokinetics of cefiderocol after single-dose or multiple-dose administration. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
cefiderocol
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on MOH_2024-01-23_013206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-23_013206.